Benzinga
13 Aug 2026, 15:21 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Cullinan Therapeutics' zipalertinib met its primary endpoint of progression-free survival in the Phase 3 REZILIENT3 trial for first-line lung cancer treatment. — Successful Phase 3 results for a first-line treatment candidate significantly increase the probability of FDA approval and future peak sales.
+0.80The FDA has accepted a New Drug Application for zipalertinib with a PDUFA target action date of February 27, 2027. — An accepted NDA provides a clear regulatory timeline and a concrete catalyst date for market valuation.
+0.60Cullinan Therapeutics reports a cash runway extending into 2029, with $356 million in liquidity as of June 30. — Strong liquidity reduces the immediate risk of dilutive financing rounds while the company awaits regulatory decisions.
+0.40Continue reading
6 related stories
Search tags
Zipalertinib is positioned as a potential competitor to J&J's Rybrevant, which is approved for the same setting but faces tolerability issues. — Competitive advantage in tolerability could allow the drug to capture significant market share from the existing standard of care.
+0.30Which stocks this story touches
The company's zipalertinib trial met its primary endpoint of progression-free survival in Phase 3.
The company's sigvotatug vedotin missed its Phase 3 overall survival goal in NSCLC.
The company's Rybrevant is noted to have tolerability issues compared to a potential competitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
17h ago
